EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Tumor cells often subvert normal regulatory mechanisms of signal transduction. This study shows this principle by studying yet uncharacterized mutants of the epidermal growth factor receptor (EGFR) previously identified in glioblastoma multiforme, which is the most aggressive brain tumor in adults. Unlike the well-characterized EGFRvIII mutant form, which lacks a portion of the ligand-binding cleft within the extracellular domain, EGFRvIVa and EGFRvIVb lack internal segments distal to the intracellular tyrosine kinase domain. By constructing the mutants and by ectopic expression in naive cells, we show that both mutants confer an oncogenic potential in vitro, as well as tumorigenic growth in animals. The underlying mechanisms entail constitutive receptor dimerization and basal activation of the kinase domain, likely through a mechanism that relieves a restraining molecular fold, along with stabilization due to association with HSP90. Phosphoproteomic analyses delineated the signaling pathways preferentially engaged by EGFRvIVb-identified unique substrates. This information, along with remarkable sensitivities to tyrosine kinase blockers and to a chaperone inhibitor, proposes strategies for pharmacological interception in brain tumors harboring EGFRvIV mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650 · cited 1×
“Because the kinase domain of WT-EGFR is intrinsically autoinhibited, and a ligand-induced dimerization promotes its activation (Zhang et al., 2006), we investigated a model attributing basal activation of the EGFRvIV mutants to constitutive receptor dimerization.”
ErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956 · cited 1×
“Growth factors and their receptors control cell-fate decisions, including survival, differentiation, proliferation or migration, and hence they have critical roles in hyperproliferative diseases, including malignancies (Hynes and MacDonald, 2009).”
Cited by
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789
“, 1992) and have been shown to be oncogenic in cellular and animal models (Cho et al., 2011; Pines et al., 2010).”
BackgroundGlioblastoma multiforme: Pathogenesis and treatment
Alifieris, C., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 820
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Harrison, P. T., Vyse, S., & Huang, P. H. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.015 · Cited by 615
Self-citationMellman, I., & Yarden, Y. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016949 · Cited by 394
Self-citationA Structural Perspective on the Regulation of the Epidermal Growth Factor Receptor
Kovacs, E., Zorn, J. A., Huang, Y., Barros, T., & Kuriyan, J. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034402 · Cited by 371
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Vyse, S., & Huang, P. H. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0038-9 · Cited by 370
Self-citationCatalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms
Jura, N., Zhang, X., Endres, N. F., Seeliger, M. A., Schindler, T., & Kuriyan, J. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.03.004 · Cited by 310
“The HER3-containing receptor heterodimers are critical for the activation of the phosphoinositide 3-kinase (PI3K)/AKT pathway by the EGF receptor family due to the exclusive presence of multiple binding sites for the p85 subunit of PI3K in the C-terminal tail of HER3 (Prigent and Gullick, 1994).”
BackgroundActivation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The “Rotation Model”
Purba, E., Saita, E.-I., & Maruyama, I. (2017) · Cells · doi:10.3390/cells6020013 · Cited by 205
“The oncogenic function of these mutants depends upon the intrinsic kinase activity [153].”
BackgroundKeppel, T. R., Sarpong, K., Murray, E. M., Monsey, J., Zhu, J., & Bose, R. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.747485 · Cited by 29
“This region has been characterized via crystallography as containing an AP2-helix and other secondary structure elements, which appear to interact with the kinase domain in a manner that inhibits activation (4, 55, 56).”
Background
Metadata
- Authors
- Pines, G., Huang, P. H., Zwang, Y., White, F. M., & Yarden, Y.
- Venue
- Oncogene
- Published
- 2010-08-02
- Volume
- 29
- Issue
- 43
- Pages
- 5850-5860
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1558729712
- Cited by
- 69
- References
- 2
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.